Ipca Laboratories
- Advice
- Hold
Ipca Laboratories Performance
Day Range
- Low 1,123.95
- High 1,153.00
52 Week Range
- Low 669.80
- High 1,153.00
- Open Price1,133.00
- Previous Close1,132.95
- Volume304454
Start SIP in Ipca Laboratories
Start SIPIpca Laboratories Investment Rating
-
Master Rating:
-
Ipca Laboratories has an operating revenue of Rs. 6,679.17 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 12% is healthy, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 11%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 15% and 35% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 64 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 1,663 | 1,489 | 1,402 | 1,433 | 1,485 | 1,469 | 1,168 |
Operating Expenses Qtr Cr | 1,354 | 1,191 | 1,226 | 1,219 | 1,213 | 1,212 | 989 |
Operating Profit Qtr Cr | 309 | 298 | 176 | 214 | 272 | 257 | 179 |
Depreciation Qtr Cr | 61 | 60 | 59 | 57 | 55 | 53 | 52 |
Interest Qtr Cr | 39 | 31 | 18 | 10 | 9 | 7 | 3 |
Tax Qtr Cr | 83 | 83 | 47 | 52 | 77 | 72 | 27 |
Net Profit Qtr Cr | 162 | 167 | 85 | 120 | 168 | 144 | 110 |
Ipca Laboratories Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹1,070.05
- 50 Day
- ₹1,008.27
- 100 Day
- ₹946.66
- 200 Day
- ₹900.26
- 20 Day
- ₹1,064.74
- 50 Day
- ₹993.82
- 100 Day
- ₹928.54
- 200 Day
- ₹845.63
Ipca Laboratories Resistance and Support
Resistance | |
---|---|
First Resistance | 1,160.48 |
Second Resistance | 1,171.27 |
Third Resistance | 1,189.53 |
RSI | 75.15 |
MFI | 82.03 |
MACD Single Line | 34.14 |
MACD | 39.29 |
Support | |
---|---|
First Resistance | 1,131.43 |
Second Resistance | 1,113.17 |
Third Resistance | 1,102.38 |
Ipca Laboratories Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 316,599 | 14,069,660 | 44.44 |
Week | 414,943 | 18,610,194 | 44.85 |
1 Month | 387,838 | 14,272,421 | 36.8 |
6 Month | 642,692 | 28,304,165 | 44.04 |
Ipca Laboratories Result Highlights
Ipca Laboratories Synopsis
NSE-Medical-Generic Drugs
Ipca Laboratorie is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 5814.62 Cr. and Equity Capital is Rs. 25.37 Cr. for the Year ended 31/03/2023. Ipca Laboratories Ltd. is a Public Limited Listed company incorporated on 19/10/1949 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1949PLC007837 and registration number is 007837.Market Cap | 29,168 |
Sales | 5,986 |
Shares in Float | 13.70 |
No of funds | 223 |
Yield | 0.17 |
Book Value | 4.96 |
U/D Vol ratio | 2.3 |
LTDebt / Equity | 11 |
Alpha | 0.11 |
Beta | 0.39 |
Ipca Laboratories
Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
---|---|---|---|---|
Promoters | 46.29% | 46.29% | 46.29% | 46.29% |
Mutual Funds | 30.23% | 30.27% | 29.94% | 29.79% |
Insurance Companies | 4.12% | 4.26% | 3.61% | 3.76% |
Foreign Portfolio Investors | 9.86% | 10.05% | 10.58% | 10.46% |
Financial Institutions/ Banks | 0.01% | |||
Individual Investors | 7.14% | 6.98% | 7.26% | 7.41% |
Others | 2.36% | 2.14% | 2.32% | 2.29% |
Ipca Laboratories Management
Name | Designation |
---|---|
Mr. Premchand Godha | Chairman & M.D & CEO |
Mr. Ajit Kumar Jain | Joint Managing Director & CFO |
Mr. Pranay Godha | Executive Director |
Mr. Prashant Godha | Executive Director |
Mr. Anand T Kusre | Independent Director |
Mr. Dev Parkash Yadava | Independent Director |
Dr.(Mrs.) Manisha Premnath | Independent Director |
Mr. Kamal Kishore Seth | Independent Director |
Ipca Laboratories Forecast
Price Estimates
Ipca Laboratories Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-11-10 | Quarterly Results & Interim Dividend | |
2023-08-10 | Quarterly Results | |
2023-05-29 | Audited Results | |
2023-02-14 | Quarterly Results | |
2022-11-11 | Quarterly Results & Interim Dividend |
Date | Purpose | Remarks |
---|---|---|
2023-11-22 | INTERIM | Rs.2.00 per share(200%)Interim Dividend (Revised) |
2022-11-23 | INTERIM | Rs.4.00 per share(400%)Interim Dividend |
2021-11-23 | INTERIM | Rs.8.00 per share(400%)Interim Dividend |
Date | Purpose | Remarks |
---|---|---|
2022-01-11 | Split | Rs.0.00 split from Rs. 2/- to Re. 1/-. |
Ipca Laboratories FAQs
What is Share Price of Ipca Laboratories ?
Ipca Laboratories share price is ₹1,149 As on 02 December, 2023 | 19:49
What is the Market Cap of Ipca Laboratories ?
The Market Cap of Ipca Laboratories is ₹29168.4 Cr As on 02 December, 2023 | 19:49
What is the P/E ratio of Ipca Laboratories ?
The P/E ratio of Ipca Laboratories is 59.3 As on 02 December, 2023 | 19:49
What is the PB ratio of Ipca Laboratories ?
The PB ratio of Ipca Laboratories is 4.9 As on 02 December, 2023 | 19:49